Health
Neoadjuvant Dual ICI Leads to Clinical Benefit in Operable NSCLC – MedPage Today
More than one-third of patients achieved major pathologic response with nivolumab-ipilimumab.
Neoadjuvant combination immunotherapy with nivolumab (Opdivo) plus ipilimumab (Yervoy) produced a significant clinical benefit for patients with operable stage I-III non-small cell lung cancer (NSCLC), researchers reported.
The phase II NEOSTAR study randomly assigned 44 patients with operable NSCLC to neoadjuvant nivolumab with or without ipilimumab followed by surgery. Among those, 38% of patients that received the combination achieved major pathological response (MPR) — defined as 10% or less…
-
General14 hours agoWoman in her 20s dies after dog attack in Western Australia’s north
-
General20 hours agoGold Coast warned it faces traffic gridlock without major shift to public transport
-
Noosa News23 hours agoDicky Bill salad greens farms enter administration with 180 job cuts just before Christmas
-
General24 hours agoAlbanese reached his zenith in 2025, but 2026 could test the limits of Labor’s power